BR112016009076A2 - Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano - Google Patents

Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano

Info

Publication number
BR112016009076A2
BR112016009076A2 BR112016009076A BR112016009076A BR112016009076A2 BR 112016009076 A2 BR112016009076 A2 BR 112016009076A2 BR 112016009076 A BR112016009076 A BR 112016009076A BR 112016009076 A BR112016009076 A BR 112016009076A BR 112016009076 A2 BR112016009076 A2 BR 112016009076A2
Authority
BR
Brazil
Prior art keywords
composition
immunogenic
calcium fluoride
preparing
processes
Prior art date
Application number
BR112016009076A
Other languages
English (en)
Inventor
Vande Velde Vincent
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of BR112016009076A2 publication Critical patent/BR112016009076A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO, PROCESSOS PARA PREPARAR UM COMPÓSITO DE FLUORETO DE CÁLCIO E UMA COMPOSIÇÃO IMUNOGÊNICA, E, USO DE UMA COMPOSIÇÃO ADJUVANTE OU DE UMA COMPOSIÇÃO IMUNOGÊNICA. Composições compreendendo compósitos de fluoreto de cálcio compreendendo Ca, F e uma molécula orgânica são providas, assim como métodos para seu uso.
BR112016009076A 2013-10-25 2014-10-23 Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano BR112016009076A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201318858A GB201318858D0 (en) 2013-10-25 2013-10-25 Calcium fluoride compositions
US201461946033P 2014-02-28 2014-02-28
PCT/EP2014/072738 WO2015059224A1 (en) 2013-10-25 2014-10-23 Calcium fluoride compositions

Publications (1)

Publication Number Publication Date
BR112016009076A2 true BR112016009076A2 (pt) 2017-10-03

Family

ID=49767142

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016009076A BR112016009076A2 (pt) 2013-10-25 2014-10-23 Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano

Country Status (8)

Country Link
US (1) US20160263214A1 (pt)
EP (1) EP3060248A1 (pt)
JP (1) JP2016535023A (pt)
CN (1) CN105873605A (pt)
BR (1) BR112016009076A2 (pt)
CA (1) CA2927652A1 (pt)
GB (1) GB201318858D0 (pt)
WO (1) WO2015059224A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111956863B (zh) * 2020-07-20 2022-05-10 广东省微生物研究所（广东省微生物分析检测中心） 一种含阴阳离子共掺杂纳米磷酸钙抗菌材料及制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2171639C (en) * 1993-09-13 1999-11-02 Laurence C. Chow Complex calcium and fluoride containing mouth rinses, dentifrices, and chewable tablets
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US20020037258A1 (en) * 1999-08-05 2002-03-28 Gregory P. Dodd Dental composition for the mineral occlusion of dentinal tubules in sensitive teeth
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US20020068090A1 (en) * 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20070218049A1 (en) * 2006-02-02 2007-09-20 Wei Chen Nanoparticle based photodynamic therapy and methods of making and using same
WO2006103112A2 (en) * 2005-03-31 2006-10-05 Lidds Ab Method for treating prostate diseases based on local delivery of active substances
MX2007015639A (es) * 2005-06-08 2008-02-15 Newbiomed Pika Pte Ltd Adyuvante basado en acido poliinosinico-acido policitidilico.
JP2011506565A (ja) * 2007-12-21 2011-03-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions

Also Published As

Publication number Publication date
WO2015059224A1 (en) 2015-04-30
EP3060248A1 (en) 2016-08-31
JP2016535023A (ja) 2016-11-10
CN105873605A (zh) 2016-08-17
US20160263214A1 (en) 2016-09-15
GB201318858D0 (en) 2013-12-11
CA2927652A1 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
CY1123324T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
NI201700011A (es) 2-(morfolin-4-il)-1,7-naftiridinas.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201591887A1 (ru) Макроциклические деазаоксипурины для лечения вирусных инфекций
UA113651C2 (xx) Макроциклічні пурини для лікування вірусних інфекцій
ECSP14017269A (es) Compuestos para tratar la atrofia muscular espinal
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
GT201400111A (es) Triazolopiridinas sustituidas
UA116083C2 (uk) Похідні пурину для лікування вірусних інфекцій
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
BR112015001619A2 (pt) manosídeos multiméricos, um processo para a preparação dos mesmos e as suas utilizações como um medicamento
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
BR112015016033A8 (pt) composições farmacêuticas para tratamento de infecções por bactérias, e seus usos
CL2015001881A1 (es) Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición.
BR112013006857A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica e método para o tratamento ou profilaxia de doenças virais
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
BR112016009076A2 (pt) Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano
EA201590782A1 (ru) Оксирановые амины

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]